Novo Nordisk (NYSE: NVO) announced plans to cut the list prices of these drugs by up to 50% in the U.S. starting in 2027, on Tuesday.

Eli Lilly on Monday launched a new form of its blockbuster obesity drug, Zepbound, that offers a month's worth of doses in a ...

Eli Lilly (LLY) stock falls as rival Novo Nordisk (NVO) plans to cut Wegovy, Ozempic & Rybelsus U.S. list prices from Jan 1, ...

Consolidation of four doses may lower secondary packaging complexity and improve fill-finish throughput predictability, although Lilly has not quantified manufacturing efficiency gains. Multi-dose use ...

Lilly’s momentum isn’t just about its successful clinical results, though. It’s also about the company’s constant iteration ...

Eli Lilly said on Monday it received the U.S. Food and Drug Administration's approval to launch a four-dose KwikPen for its weight-loss drug Zepbound, delivering a full month of the treatment in a ...

Pharmaceutical giant Eli Lilly and Company (NYSE:LLY)’s shares are up by 23.5% over the past year and down by more than 1% ...